Investor profile
Forbion
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Forbion is a global venture capital firm dedicated to advancing groundbreaking biotech innovations and other sustainable solutions that improve the health of people and the planet. The firm manages approximately €5 billion across multiple fund strategies — Ventures, Growth, Formation (via BGV joint venture), and BioEconomy — covering all stages of (bio)pharmaceutical drug development from pre-seed company creation through late-stage clinical growth capital, crossover, and public market investments. Forbion's Ventures funds build and enable innovative therapeutics-focused biotechs, primarily at Series A and B, with a prime focus on Europe, while its Growth strategy provides private growth capital for clinical-stage drug development. Its BioEconomy fund extends the firm's biotech expertise to planetary health, investing in companies leveraging biotechnology across food, agriculture, materials, and environmental technologies.
Notable quotes
“Investing in the LS space can be very rewarding as financial success is often coupled to success for patients in new drugs and devices for high needs reaching the markets.”
“This being the fourth generation fund and having kept the same core team over time, we have a good track record, which significantly helped new LPs to come on board.”
“This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan's in vivo CAR-T technology.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Expedition Therapeutics | Series A | $165m | 2025 |
| Azafaros | Series B | $147m | 2025 |
| Sparrow Pharmaceuticals | Series B | $95m | 2025-09 |
| Tropic Biosciences | Series C | $105m | 2026 |
| Orbis Medicines | Series A | $100m | 2025-01 |
| Genomines | Series A | $45m | 2025 |
| argenx | Series A | — | 2012 |
| uniQure | Series A | — | 2012 |
| NewAmsterdam Pharma | Series B | — | 2021 |
| Beacon Therapeutics | Series B | — | 2023 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| RA Capital Management | 10 |
| Novo Holdings | 6 |
| Novartis Venture Fund | 6 |
| OrbiMed | 5 |
| Sofinnova Partners | 4 |
| BioGeneration Ventures (BGV) | 4 |
Fit check
Is Forbion a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit